• US: +1 9176726599
  • Login

Transdermal Drug Delivery Devices Market Status (2016-2020) and Forecast Market Analysis, Regional Outlook, Segment Growth Potential, and Competitive Market Share Analysis, 2021-2027

Format: PDF | Pages: 354 | Report ID: MRS1114


Report Description

The global Transdermal Drug Delivery Devices Market size is estimated at USD 58,008.9 million in 2020, expanding at a CAGR 9.8% from 2021-2027 to reach 66,512.7 Million USD in 2027.

Market Dynamics

Transdermal drug delivery devices transport medications via the skin for therapeutic purposes are an alternative to oral intravenous, transmucosal, and subcutaneous routes. The increase in the elderly population and the rise in the number of people suffering from chronic illnesses are likely to drive market expansion. Furthermore, the increased usage of third-generation transdermal drug delivery techniques, such as iontophoresis, drives market expansion. However, drawbacks of these delivery methods, such as discomfort and edema at the site of administration, are projected to stymie market expansion.

The market has seen the introduction of novel molecular absorption enhancers, adhesives, and penetration enhancing drugs that are projected to improve skin permeability, resulting in an increase in the number of medications that are expected to be supplied through the transdermal method. For example, modern technology, such as tiny needle-enhanced administration, allows for convenient medication transfer over the skin without the sense of discomfort.

Regional Insights

North America is a significant revenue generator in the transdermal delivery systems industry. The region's transdermal delivery device market is being driven by the increasing prevalence of aimed diseases (such as central nervous system disorders, chronic pain, and cardiovascular diseases), the increasing use of contraception, and the growing number of transdermal drug delivery system research activities.

Segment Insights

Pain management is predicted to have the greatest market share in the Transdermal Drug Delivery Devices Market application segment. The cause for this is the growing global burden of chronic pain problems, as well as the rising number of transdermal products and developing of pain management.

According to the National Center for Health Statistics' Chronic Pain and High-impact Chronic Pain Among U.S. Adults, 2019 statistics, in the year 2019, 20.4 percent of adults had chronic pain and 7.4 percent of adults had chronic pain which is commonly restricted life or work activities (known as high affect chronic pain) in the previous 3 months. Chronic pain and rising chronic pain both become worse with age and were thought to be most prevalent in persons 65 and older. The overall prevalence of chronic pain was 20.4 percent, with a mainly high chronic pain of 7.4 percent. As the incidence of chronic pain problems rises, there will be a greater need for transdermal medication delivery systems for pain treatment, propelling the market growth.

Competitive Insights

Mylan, Hisamitsu Pharmaceutical, Novartis, UCB SA, Boehringer Ingelheim, GlaxoSmithKline, Endo International, Johnson & Johnson, Bristol-Myers Squibb Company, Purdue Pharma, Acrux Limited, Endo Pharmaceuticals Inc., Luye Pharma Group, Lavipharm, Lead Chemicals Co. Inc., and others are among the key market players operating in the Transdermal Drug Delivery Devices market. Hisamitsu Pharmaceutical Co., Inc. announced on December 07, 2020, that topically applied, pain treatment NSAID patch had accomplished the primary outcome of the LP03 study, Phase III clinical study for "low back pain," and the LP04 study, Phase III medical trial for "humeroscapular periarthritis, cervico-omo-brachial syndrome, and tenosynovitis" in Asia.

The report begins with an overview of the Industry Chain structure, describes the industry environment, then analyses the market size and forecast of Transdermal Drug Delivery Devices market by Type, Application, end-uses, and region. In addition, this report introduces the market competition situation among the vendors, and company profile, besides, market price analysis, and value chain features are covered in this report.

Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):

  • Mylan
  • Hisamitsu Pharmaceutical
  • Novartis, UCB SA
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Endo International
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Purdue Pharma
  • Acrux Limited
  • Endo Pharmaceuticals Inc.
  • Luye Pharma Group
  • Lavipharm, Lead Chemicals Co. Inc.
  • F. Hoffmann-La Roche Ltd.

Type Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • Drug-In-Adhesive Patches
  • Matrix Patches
  • Microneedle Patches
  • Reservoir Membrane Patches

Application Type Coverage (Market Size & Forecast, Main Consumer Analysis etc.):

  • Cardiovascular Diseases
  • Central Nervous System Disorders
  • Hormonal Applications
  • Pain Management
  • Others

End-Use Coverage (Market Size & Forecast, Main Consumer Analysis etc.):

  • Hospitals
  • Ambulatory Surgical Centers
  • Others  

Region Coverage (Regional Consumption, Demand & Forecast by Countries etc.):

  • North America (U.S., and Canada)
  • Europe (Germany, U.K., France, Italy, Spain etc.)
  • Asia-Pacific (China, India, Japan, Indonesia, Malaysia, Australia, South Korea, etc.)
  • South America (Brazil, Mexico, Argentina etc.)
  • Middle East & Africa (Saudi Arabia, Kuwait, UAE, South Africa etc.)

Frequently Asked Questions

The global Transdermal Drug Delivery Devices Market size is estimated at USD 58,008.9 million in 2020, expanding at a CAGR 9.8% from 2021-2027 to reach 66,512.7 Million USD in 2027.
North America captured the highest revenue in 2021 and is projected to continue its dominance during the study period.
The global Sensing Cable Market size is expanding at a CAGR 6.3% from 2021-2027 to reach 1,300.5 Million USD in 2027.
Asia Pacific (especially China, and India) region is projected to grow at the fastest growth rate during the study period.
Mylan, Hisamitsu Pharmaceutical, Novartis, UCB SA, Boehringer Ingelheim, GlaxoSmithKline, Endo International, Johnson & Johnson, Bristol-Myers Squibb Company, Purdue Pharma, Acrux Limited, Endo Pharmaceuticals Inc., Luye Pharma Group, Lavipharm, Lead Chemicals Co. Inc., and others are among the key market players operating in the Transdermal Drug Delivery Devices market. Hisamitsu Pharmaceutical Co., Inc. announced on December 07, 2020, that topically applied, pain treatment NSAID patch had accomplished the primary outcome of the LP03 study, Phase III clinical study for "low back pain," and the LP04 study, Phase III medical trial for "humeroscapular periarthritis, cervico-omo-brachial syndrome, and tenosynovitis" in Asia.

Why Choose Market Research Strategy?

  Authenticated Data Sources

We utilize market analysis/information from verified authenticated data sources to scoop accurate research reports

  Express Delivery

We understand the urgency of our clients and their clients' in the competitive space thus, deliver the report in minimum turnaround

  Gain Instant Access

Without further ado, choose us and get instant access to reliable analysis to help you make the right business decisions.

  Our Pledge to You

We abide by the information security policy and adheres to keep your private and business information confidential and secure.

Copyright © 2022 Market Research Strategy, All rights reserved.